Nasdaq · CIK 0001853816
DRMA Dermata Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jan 23, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Dermata Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 19 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 21, 2025 | Gerald T Proehl President, CEO and Chairman | AGrant or award Common Stockindirect: By Proehl Investment Ventures LLC | +787,402 | - | - | 799,508 | Jan 23, 2025 |
| Jan 21, 2025 | Kyri K. Van Hoose SVP, CFO | AGrant or award Common Stock | +78,741 | - | - | 78,741 | Jan 23, 2025 |
| Jan 21, 2025 | Mary Fisher director | AGrant or award Common Stock | +196,851 | - | - | 196,946 | Jan 23, 2025 |
| Jan 23, 2025 | David F Hale director | AGrant or award Common Stockindirect: By Hale BioPharma Ventures LLC | +78,741 | - | - | 80,957 | Jan 23, 2025 |
| Jan 21, 2025 | Kyri K. Van Hoose SVP, CFO | AGrant or award Warrant (Right to Buy)derivative | +78,741 | - | - | 78,741 | Jan 23, 2025 |
| Jan 21, 2025 | Mary Fisher director | AGrant or award Warrant (Right to Buy)derivative | +196,851 | - | - | 196,851 | Jan 23, 2025 |
| Jan 21, 2025 | David F Hale director | AGrant or award Warrant (Right to Buy)derivativeindirect: By Hale BioPharma Ventures LLC | +78,741 | - | - | 78,741 | Jan 23, 2025 |
| Jan 21, 2025 | Gerald T Proehl President, CEO and Chairman | AGrant or award Warrant (Right to Buy)derivativeindirect: By Proehl Investment Ventures LLC | +787,402 | - | - | 787,402 | Jan 23, 2025 |
| Jan 13, 2025 | Andrew Seth Sandler director | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 14, 2025 |
| Jan 13, 2025 | Christopher J. Nardo Senior VP, CDO | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jan 14, 2025 |
| Jan 13, 2025 | David F Hale director | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 14, 2025 |
| Jan 13, 2025 | Wendell Wierenga director | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 14, 2025 |
| Jan 13, 2025 | Mary Fisher director | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 14, 2025 |
| Jan 13, 2025 | Kyri K. Van Hoose SVP, CFO | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jan 14, 2025 |
| Jan 13, 2025 | Gerald T Proehl President, CEO and Chairman | AGrant or award Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jan 14, 2025 |
| Jan 13, 2025 | Steven J Mento director | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 14, 2025 |
| Jan 13, 2025 | Kathleen D. Scott director | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 14, 2025 |
| Jan 13, 2025 | Brittany Bradrick director | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 14, 2025 |
| Jan 13, 2025 | Munera Maria E Bedoya-Toro SVP, Regulatory Affairs | AGrant or award Stock Option (right to buy)derivative | +8,000 | $0.00 | $0 | 8,000 | Jan 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Munera Maria E Bedoya-ToroSVP, Regulatory Affairs
- Brittany Bradrickdirector
- Mary Fisherdirector
- David F Haledirector
- Steven J Mentodirector
- Christopher J. NardoSenior VP, CDO
- Gerald T ProehlPresident, CEO and Chairman
- Andrew Seth Sandlerdirector
- Kathleen D. Scottcfo, officer, director
- Kyri K. Van HooseSVP, CFO
- Wendell Wierengadirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.